Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression in vascular smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 12, 1999, Pages 3025-3032

  Dichtl, Wolfgang ^a,b,d   Stiko, Ann ^b   Eriksson, Per ^b   Goncalves, Isabel ^a   Calara, Federico ^a   Banfi, Cristina ^c   Ares, Mikko P S ^a   Hamsten, Anders ^b   Nilsson, Jan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MILAN   (Italy)

^d Malmö University Hospital   (Sweden)

Author keywords

Activator protein 1; Lipid oxidation; Lysophosphatidylcholine; Plasminogen activator inhibitor 1; Smooth muscle cells

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROBUCOL; TISSUE PLASMINOGEN ACTIVATOR; TRANSCRIPTION FACTOR AP 1; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR SMOOTH MUSCLE;

EID: 0033373547     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.12.3025     Document Type: Article

References (44)

1. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A. 1992;89:6998-7002.
2. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
3. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost. 1994;72:44-53.
4. Christ G, Hufnagel P, Kaun C, Mundigler G, Laufer G, Huber K, Wojta J, Binder BR. Antifibrinolytic properties of the vascular wall: dependence on the history of smooth muscle cell doublings in vitro and in vivo. Arterioscler Thromb Vasc Biol. 1997;17:723-730.
5. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69: 381-387.
6. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16: 207-216.
7. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
8. Murphy G, Ward R, Gavrilovic J, Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix Suppl. 1992;1:224-230.
9. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation. 1997;96:3180-3191.
10. Palinski W, Rosenfeld ME, Ylä-Herttuala, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, Witztum JL. Low density lipoprotein undergoes modification in vivo. Proc Natl Acad Sci U S A. 1989; 86:1372-1376.
11. Ylä-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL. Evidence for presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086-1095.
12. Henriksen T, Mahoney EM, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc Natl Acad Sci U S A. 1981;78:6499-6503.
13. Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
14. Regnström J, Nilsson J. Lipid oxidation and inflammation-induced intimal fibrosis in coronary heart disease. J Lab Clin Med. 1994;124:162-168.
15. Frostegård J, Wu R, Haegerstrand A, Patarroyo M, Lefvert A-K, Nilsson J. Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules. Atherosclerosis. 1993;103:213-219.
16. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AL. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87: 5134-5138.
17. Frostegård J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U 937. Proc Natl Acad Sci U S A. 1990;87:904-908.
18. Jovinge S, Ares M, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-α in response to ox-LDL. Arterioscler Thromb Vasc Biol. 1996;16:1573-1579.
19. Stiko-Rahm A, Hultgårdh-Nilsson A, Regnström J, Hamsten A, Nilsson J. Oxidized and native LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human arterial smooth muscle cells. Arterioscler Thromb. 1992;12:1099-1109.
20. Ares MPS, Kallin B, Eriksson P, Nilsson J. Oxidized low density lipoprotein induces transcription factor activator protein-1 but inhibits activation of nuclear factor-κB in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995;15:1584-1590.
21. Stiko A, Regnström J, Shah PK, Cercek B, Nilsson J. Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein induced activation of smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol. 1996;16:194-200.
22. Calara F, Dimayuga P, Niemann A, Thyberg J, Diczfalusy U, Witztum JL, Palinski W, Shah PK, Cercek B, Nilsson J, Regnström J. An animal model to study the local oxidation of LDL and its biological effects in the arterial wall. Arterioscler Thromb Vasc Biol. 1998;18:884-893.
23. Palinski W, Ylä-Herttula S, Rosenfeld M, Buller S, Socher S, Parthasarathy S, Curtiss L, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
24. Redgrave TG, Carlson LA. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo-and hypertriglyceridemic man. J Lipid Res. 1979;20:217-229.
25. Lowry O, Rosebrough N, Farr A, Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
26. Cercek B, Yamashita M, Dimayuga P, Zhu J, Fishbein MC, Kaul S, Shah PK, Nilsson J, Regnström J. Nuclear factor-κB activity and response to balloon injury. Atherosclerosis. 1997;131:59-66.
27. Bruzdzinski C, Riordan-Johnson M, Nordby E, Suter SM, Gelehrter TD. Isolation and characterization of the rat plasminogen activator inhibitor-1 gene. J Biol Chem. 1990;265:2078-2085.
28. Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984;4:357-364.
29. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis. 1990;10: 1067-1073.
30. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, Juhan-Vague I. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821-1829.
31. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb. 1992;12:19-27.
32. Tremoli E, Camera M, Madema P, Sironi L, Prati L, Colli S, Piovella F, Bernini F, Corsini A, Mussoni L. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: an LDL receptor-independent phenomenon. Arterioscler Thromb. 1993;13:338-346.
33. Chautan M, Latron Y, Anfosso F, Alessi MC, Lafont H, Juhan-Vague I, Nalbone G. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells. J Lipid Res. 1993;34:101-110.
34. Eriksson P, Nilsson L, Karpe F, Hamsten A. A very low density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20-26.
35. Kugiyama K, Sakamoto T, Misumi I, Sugiyama S, Ohgushi M, Ogawa H, Horisuchi M, Yasue H. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 1993;73: 335-343.
36. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. J Biol Chem. 1991;266: 23048-23052.
37. Descheemaeker KA, Wyns S, Nelles L, Auwerx J, Ny T, Collen D. Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem. 1992; 267:15086-15091.
38. Arts J, Grimbergen J, Bosma PJ, Rahmsdorf HJ, Kooistra T. Role of c-Jun and proximal phorbol 12-myristate-13-acetate-(PMA)-responsive elements in the regulation of basal and PMA-stimulated plasminogen-activator inhibitor-1 gene expression in HepG2. Eur J Biochem. 1996;241:393-402.
39. Arts J, Grimbergen J, Toet K, Kooistra T. On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1α in HepG2 cells. Arterioscler Thromb Vasc Biol. 1999;19:39-46.
40. van Hinsbergh VW, Binnema D, Scheffer MA, Sprengers ED, Kooistra T, Rijken DC. Production of plasminogen activators and inhibitor by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis. 1987;7:389-400.
41. Sawa H, Lundgren C, Sobel BE, Fujii S. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury: a potential progenitor of restenosis. J Am Coll Cardiol. 1994;24:1742-1748.
42. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells: expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res. 1996; 78:405-414.
43. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93-99.
44. Bochaton-Piallat ML, Gabbiani G, Pepper MS. Plasminogen activator expression in rat arterial smooth muscle cells depends on their phenotype and is modulated by cytokines. Circ Res. 1998;82:1086-1093.